key: cord-0715814-pjynkv9d
authors: Lumbers, Eugenie R.; Head, Richard; Smith, Gary R.; Delforce, Sarah J.; Jarrott, Bevyn; H. Martin, Jennifer; Pringle, Kirsty G.
title: The interacting physiology of COVID‐19 and the renin‐angiotensin‐aldosterone system: Key agents for treatment
date: 2022-02-01
journal: Pharmacol Res Perspect
DOI: 10.1002/prp2.917
sha: b8e9399fdbbd0a1bee1ddfcd5d2dee3f2b7a8711
doc_id: 715814
cord_uid: pjynkv9d

SARS‐CoV‐2 interacting with its receptor, angiotensin‐converting enzyme 2 (ACE2), turns the host response to viral infection into a dysregulated uncontrolled inflammatory response. This is because ACE2 limits the production of the peptide angiotensin II (Ang II) and SARS‐CoV‐2, through the destruction of ACE2, allows the uncontrolled production of Ang II. Recovery from trauma requires activation of both a tissue response to injury and activation of a whole‐body response to maintain tissue perfusion. Tissue and circulating renin‐angiotensin systems (RASs) play an essential role in the host response to infection and injury because of the actions of Ang II, mediated via its AT(1) receptor. Both tissue and circulating arms of the renin angiotensin aldosterone system's (RAAS) response to injury need to be regulated. The effects of Ang II and the steroid hormone, aldosterone, on fluid and electrolyte homeostasis and on the circulation are controlled by elaborate feedback networks that respond to alterations in the composition and volume of fluids within the circulatory system. The role of Ang II in the tissue response to injury is however, controlled mainly by its metabolism and conversion to Ang‐(1‐7) by the enzyme ACE2. Ang‐(1‐7) has effects that are contrary to Ang II‐AT(1)R mediated effects. Thus, destruction of ACE2 by SARS‐CoV‐2 results in loss of control of the pro‐inflammatory actions of Ang II and tissue destruction. Therefore, it is the response of the host to SARS‐CoV‐2 that is responsible for the pathogenesis of COVID‐19.

This article describes how SARS-CoV-2, by interacting with its receptor, angiotensin converting enzyme 2 (ACE2), turns the host response to infection into a dysregulated uncontrolled inflammatory response. We describe the multiple pathways via which angiotensin (Ang) II is involved in the inflammatory response and, with the evidence presented in this article, make the case that blockade of the actions of Ang II should be seriously considered as a therapeutic pathway for patient treatment in COVID-19. This conclusion is sup- ACE2 is a highly conserved protein, it appeared early in evolution, about 550 million years ago, as it is found in chordates like Ciona intestinalis. 4 All examples of human viruses with broad host ranges use highly conserved cell receptors (i.e., with more than 90% amino acid sequence homology).

ACE2 is a component of the renin-angiotensin system (RAS, Figure 1 ). The RAS is an ancient system with most genes appearing in the Paleozoic period, so that the key components of the RAS pathways ( Figure 1 ) are present in amphibians. 4 Since angiotensin (Ang) II is the major peptide formed by the RAS and its major receptors (AT 1 R and AT 2 R) also appeared very early, close to the appearance of ACE and ACE2,, it follows that Ang II has been biologically significant throughout evolution. 4 It is this system that is responsible for the pathological host response, including morbidity and death, to COVID-19 infection. To understand the pathophysiology of COVID-19 and before potential treatments of COVID-19 can even be considered, it is therefore necessary to understand the role(s) of this ancient system and of ACE2.

Primitive Homo sapiens first emerged about 300 000 years ago as hunter gatherers. They lived in small groups with minimal exposure to infection but maximum exposure to trauma. Trauma involves injury, damage to tissues and cells, and blood loss. To recover from trauma requires activation of both a tissue response to injury/infection and activation of a whole-body response to maintain tissue perfusion. Tissue and circulating RASs fulfill both roles. Thus, the RAAS (renin-angiotensin aldosterone system) can be seen as an integrated system acting at both the cellular level and as an endocrine system coordinating the whole-body response to injury/infection. Ang II interacting with its receptor, the Ang II type 1 receptor (AT 1 R), is the major pathway coordinating this "emergency" response system. Although the Ang II-AT 1 R pathway is essential for survival, from the time of birth it can, if overexpressed, cause damage to both tissues and systems. This is most clearly demonstrated by the fact that many of the comorbidities suffered by Homo sapiens in the 21st century are due to damage that involves an overactive Ang II-AT 1 R pathway (e.g., damaging effects of diabetes mellitus, hypertension, glomerulosclerosis, and cardiac fibrosis).

We propose that both the circulating (RAAS) and tissue reninangiotensin (RAS) systems are always tonically active, and that these and other Ang II forming systems activate the AT 1 R to maintain cellular and tissue integrity both by local paracrine/autocrine actions and by integration of homeostatic regulation of tissue perfusion and blood pressure. ACE2 is the major protease regulating the activity of the Ang II-AT 1 R although there are other pathways that can also degrade Ang II to produce Ang-(1-7) ( Figure 1 ).

When SARS-CoV-2 enters cells by binding to ACE2; it stimulates local Ang II production. This recruits innate defense mechanisms. It also destroys ACE2 and so leaves Ang II-AT 1 R induced inflammation unchecked. It follows that if the viral load is low, the effects of SARS-CoV-2 infection will minimal, but in those situations in which Ang II production is tonically activated, for example, obesity, hypertension, and diabetes mellitus, where it is likely that ACE2 receptor density is increased, SARS-CoV-2 will infect tissues more avidly, the Ang II-AT 1 R pathway will be activated more intensely, and the inflammatory response will be more severe.

A clear example of this that ACE2 y/− mice do not get SARS-CoV spike protein induced lung inflammation whereas ACE2 y/+ do. 9 Thus it is not surprising that obesity also induces a more severe inflammatory response and worse outcomes in patients with Some patients infected with SARS-CoV-2 experience a hyperinflammatory response known as a "cytokine storm." It is this overwhelming release of pro-inflammatory cytokines and, in the case of COVID-19, suppressed levels of anti-inflammatory cytokines that causes the severe lung and tissue damage seen in COVID-19. This article describes the role of the RAAS in the host response to COVID-19 infection because it is the components of this system (activation of the ACE-Ang II-AT 1 R axis, suppression of the ACE2-Ang-(1-7)-MasR axis) that initiate and determine the morbidity and mortality associated with this infection. However, when discussing the host response to SARS-CoV-2, it is important to realize that: 4. the inflammatory response involves the migration of cells to the site of infection (partly through the effects of locally produced Ang II). As these cells contain Ang II-producing pathways, they bring the peptide to the site of inflammation and so enhance the Ang II-AT 1 R induced response within the tissue 5. the degree of protection offered by the ACE2 pathway in preventing severe inflammation cannot be over emphasized. ACE2 is anti-inflammatory because it: a. metabolizes Ang II; b. converts Ang II to Ang-(1-7); and c. Ang-(1-7) acts via MasR, AT 2 R, and MgrD to block proinflammatory pathways mediated by Ang II and other peptides that interact with the AT 1 R ( Figure 1 ).

Thus, destruction of ACE2 results in overexposure of cells to Ang II. Since Ang II can be produced by both extracellular and intracellular pathways this means that both blockade of ACE by angiotensin converting enzyme inhibitors (ACEIs) and Ang II-AT 1 R receptor blocking drugs (ARBs) may not necessarily fully protect against the loss of ACE2 because they cannot enter the cell.

Only the kidney releases both active renin and inactive renin (prorenin) into the circulation. Production of Ang II by active renin from its substrate angiotensinogen (AGT), is finely controlled by several feedback pathways that can be simple and direct, that is, F I G U R E 1 Angiotensin peptides, their synthesis, and their receptors. Green boxes indicate those pathways activating the proinflammatory Angiotensin II type 1 receptor (AT 1 R). Purple boxes indicate those pathways that result in formation or actions of antiinflammatory Ang peptides. Active renin is the major catalytic enzyme that produces Angiotensin (Ang) I from angiotensinogen. Other proteases can produce Ang-(1-12) and (1-25) from angiotensinogen. These peptides can then be catalyzed to smaller active Ang peptides. Prorenin is the inactive form of renin which can produce Ang I if bound to the prorenin receptor or if activated by proteases (see Figure 2 ). Angiotensin converting enzyme (ACE) converts Ang I to Ang II, the major peptide acting on the AT 1 R, which can also act on the AT 2 R. Ang II can be metabolized by aminopeptidase A (APA) to Ang III and Ang IV by Aminopeptidase N (APN). Ang IV is a ligand for insulin regulated aminopeptidase (IRAP). Ang II is the major substrate for ACE2, which converts it to Ang-(1-7). Ang-(1-7) can also be formed from Ang II via Ang A (which is produced by Mononuclear Leucocyte-Derived Aspartate Decarboxylase (MLDAD) and ACE2, which converts it to Alamandine (Ala-Ang-(1-7)). Thus, there are alternative pathways that can generate Ang-(1-7), see also its formation from Ang I by the interaction of ACE2 and neprilysin (NEP). Ang-(1-7) acts on the MasR and the AT 2 R and Ang-(1-7) and Ala 1 Ang-(1-7) can act on Mas-related G protein-coupled receptor D (MgrD). AD, Aspartate Decarboxylase 6,7 mediated by Ang II interacting with its AT 1 R (blocking renin release), or elaborate and indirect. Figure 3 shows the major organs involved in the integrated control of circulating Ang II concentrations. Ang II controls aldosterone secretion from the zona glomerulosa of the adrenal gland which, along with the intrarenal RAS, is critical in maintaining/restoring blood volume.

The major complex feedbacks controlling active renin release from juxtaglomerular cells in the renal afferent arteriole can be direct or involve intermediary neural pathways such as high-and lowpressure baroreceptors. They include control by renal perfusion pressure and the macula densa (MD), a sensor of intra-renal tubular Na + concentration as well as centrally mediated renal sympathetic F I G U R E 2 Alternate pathways that can produce Angiotensin (Ang) II. These pathways are important for cellular and tissue production of Ang II. Dotted lines indicate the pathways where intermediate peptides have not been described. t-PA, tissue plasminogen activator. Note some of these enzymes can activate prorenin as well as forming Ang II from larger Ang peptides. Derived from Belova 8 F I G U R E 3 Key organs involved in the circulating renin-angiotensin system (RAS). Renin forms angiotensin (Ang) I from angiotensinogen (AGT). Renin secreted into renal venous blood and renal lymph forms Ang I. Angiotensin converting enzyme (ACE) converts Ang I to Ang II; ACE2 converts Ang II to Ang-(1-7). Note that although kidney and tissues can form Ang II from Ang I, a major site for the conversion of circulating Ang I to Ang II is the lung. Ang II enters the arterial circulation and acts on the brain, activating sympathetic outflow and inhibiting parasympathetic (vagal) outflow. Thus, centrally acting Ang II affects cardiac output and peripheral vascular resistance via the sympathetic nervous system (SNS) and directly affects blood vessels and cardiac output so that blood pressure is increased. Renal secretion of renin is controlled by renal baroreceptors, the renal SNS and the macula densa. ACE2 is found in all sites where Ang II acts via AT 1 Rs. Thus SARS-CoV-2 can infect renal, vascular, lung, brain, and cardiac tissues (possibly by vascular endothelial infection) as well as any other tissues possessing ACE2 (gut, pancreas, testis, and ovary). Destruction of ACE2 in these tissues causes inflammation, organ dysfunction and ultimately fibrosis nerve activity. Thus, the circulating RAS is controlled in response to homeostatic demand mediated by controlling renin release.

Angiotensinogen (AGT), the substrate of renin, is formed in the liver. Its production is stimulated by estrogens and by Ang II. 17 Therefore, there is, a feed forward mechanism involved in controlling circulating AGT and a feedback system controlling renin secretion. It should be noted that although these organs have been highlighted as playing critical roles in the formation and control of the endocrine RAS they also possess paracrine/autocrine RASs which together with the endocrine RAS make them more susceptible to the adverse effects of destruction of ACE2 by SARS-CoV-2.

Angiotensin II, which is increased in patients with COVID-19, stimulates aldosterone production via its actions on the AT 1 R. Aldosterone is a key effector in the RAS and is involved in sodium homeostasis.

Aldosterone is however regulated by other humoral factors, for example, ACTH, sodium, and potassium concentrations. Aldosterone acts via its mineralocorticoid receptor (MR) which also has proinflammatory actions. 18 With destruction of ACE2 by SARS-CoV-2, Ang II levels rise leading to increased aldosterone levels. Aldosterone and Ang II acting in concert cause inflammation 19 because like Ang II, aldosterone activates NADPH and the NF-κB pro-inflammatory pathway. 20 Drugs like spironolactone and eplerenone, which block the mineralocorticoid receptor (MR), are anti-inflammatory and antifibrotic. MRs as well as Ang II-AT 1 Rs occur in cells of the innate immune system. Aldosterone works in concert with Ang II in promoting the host response to COVID-19, particularly because Ang II through the generation of ROS makes the MR no longer aldosterone selective, leading to generation of ATP, activation of Weibel-Palade bodies, clotting and increased capillary permeability. 19 

A number of enzymes in addition to renin can produce Ang II ( Figure 2 ) and, in tissues, there is no complex homeostatic regulation of these angiotensin producing systems such as those controlling the circulating RAS. Tissue angiotensin-producing systems, many of which express renin, have been found in most organs, tissues, and cells of the body (e.g., heart, lung, brain, eye, gut, male and female reproductive tracts and kidneys) as well as adipose tissue. 21 Tissues do not secrete active renin, they constitutively release prorenin. To produce Ang I from AGT, prorenin has to be activated either by proteolytic enzymes (such as trypsin, cathepsin D and plasmin) that remove its 28 amino acid pro-segment [22] [23] [24] or by binding of prorenin to the (pro)renin receptor ((P)RR). 25 Prorenin binding to the (P)RR results in unfolding of the prorenin molecule so that its catalytic site is exposed and AGT can bind to it and form Ang I. (P) RR forms an integral part of membrane bound vacuolar (v)-ATPase.

Since v-ATPases result in the extrusion of protons it is tempting to suggest that the (P)RR in conjunction with its ability to bind and unfold prorenin, is involved in converting prorenin to active renin by lowering extracellular pH and activating prorenin cleaving enzymes such as cathepsin D. 26 Cathepsin D is increased in plasma following myocardial infarction and may contribute to Ang II production 27 like other enzymes ( Figure 2 ). (P)RR can be produced as an independent moiety by lysosomal enzymes and is secreted in a soluble form (s(P) RR) which increases the catalytic activity of renin on oxidized AGT 28 but can also act as an AT 1 R agonist. 14 For renin to produce Ang II and activate the AT 1 R, Ang I, the decapeptide produced by its action on AGT, must be converted to Ang II by the dipeptidase ACE ( Figure 1 ). ACE is an ectoenzyme situated on the cell membrane. While ACE controls the formation of Ang II it also degrades another peptide, bradykinin, producing des-Arg9-bradykinin (DABK). DABK acts as an agonist on the B1 bradykinin receptor, which is activated in inflammation and upregulated when ACE2 destroyed. 29 ACE2, a homologue of ACE is also membrane-bound and metabolizes Ang II, forming Ang-(1-7) and DABK. Thus, production and hydrolysis of angiotensin and bradykinin peptides are linked because the two key proteases of the RAS, ACE, and ACE2 ( Figure 1 ) control their production and actions. 30 It is also important to remember that prorenin, renin and ACE are not the only enzymes capable of forming Ang II from AGT or Ang I.

Chymase, trypsin, and cathepsins can also generate Ang II ( Figure 2 ). 8

Chymase can convert Ang I to Ang II and is probably the major converting enzyme in the heart. 31 Chymase is also the major enzyme responsible for producing Ang II from Ang-(1-12) (Ang I-Val 11 -Ileu 12 ). 32, 33 This pathway is obviously resistant to inhibition by renin inhibitors or by ACE inhibitors. Chymase can also cleave Ang II from BigAng25 (BAng-25), a 13 amino acid extended C-terminus peptide of Ang-(1-12). BAng-25 has been found in urine. These other Ang II producing pathways may be significant for intracrine production of Ang II. Since neither ACE inhibitors (ACEIs) nor angiotensin receptor blockers (ARBs) can target these intracellular pathways these mechanisms of production of Ang II are resistant to their actions. 34 

Feedback mechanisms for controlling the activity of tissue RASs are not as refined as those that exist for managing the circulating RAAS.

The major enzyme degrading Ang II and producing Ang-(1-7) is ACE2, although there are alternate pathways that produce Ang-(1-7) which, by interacting with AT 2 R, MgrD, or MasR, has anti-inflammatory actions ( Figure 1 ). However, Ang II is the major substrate for ACE2, and its removal by ACE2 is paramount to reducing its pro-inflammatory effects. There is evidence that ACE2 is upregulated when tissue Ang II peptides are increased, for example, in the heart, in cardiac myocytes in both dilated and hypertrophic cardiomyopathy 35 but whether this is a simple feedback mechanism due to the Law of Mass action or involves more complex intracellular control is unknown.

Another receptor known to counteract the actions of Ang II on the AT 1 R is the AT 2 R, which is also found to be more transiently but highly expressed in inflamed and healing tissues in adults. 36 

ACE2 controls the anti-inflammatory arm of the RAS. It is a monocarboxypeptidase that can also produce Ang-(1-9) from Ang I ( Figure 1 ). Acting in conjunction with ACE, ACE2 can therefore produce Ang-(1-7) via this route. However, its major substrate is Ang II and its ability to metabolize Ang II must be considered significant in Briefly, the SARS-CoV-2 spike protein (S protein) is essential for binding and entry to ACE2 into the cell; it has two functional components which must be separated from each other for complete viral entry. The S1 domain binds to ACE2 via its receptor-binding domain (RBD) which contains the receptor-binding motif (RBM, 438-506).

The RBM binds to ACE2 and determines the affinity of SARS-CoV-2 for ACE2. The S2 domain contains three sequences necessary for cell entry. The spike contains a proprotein convertase (PPC) subunit at the S1/S2 boundary, which Shang et al. showed to be critical for viral entry. 37 Furin is responsible for S1/S2 cleavage. Lysosomal cathepsins and the surface protease, TMPRSS2, also facilitate cell entry. Shang et al. showed that all three of these enzymes (furin, cathepsin and TMPRSS2) cumulatively facilitate cell entry but furin pre-activation allows the virus to enter a variety of cells more readily, including those low in the expression of TMPRSS2 and cathepsins. 37 Protease activation causes a structural change in the virus essential for its fusion via S2 with the cell membrane. Although SARS-CoV-2 RBD binds to ACE2 with a greater affinity than SARS-CoV RBD 38 the spike protein itself has an affinity similar to or less than SARS-CoV. This is because the RBD of SARS-CoV-2 is most often hidden from the surface which enhances its ability to evade immune defense mechanisms, but it has to "stand up" to bind to ACE2. The SARS-CoV RBD is on the other hand usually in a "standing up" position. 37 Descending infections of the respiratory tract cause inflammation in the lung. In the gastrointestinal tract ACE2 is most highly expressed in the small intestine where it is found on enterocytes and is involved neutral amino acid transport. ACE2 expression increases with age. 39 Within the body SARS-CoV-2 gains access to heart and kidneys via infection of the vascular endothelium; similar infection of the brain vascular system is due to endothelial spread of the virus and subsequent vascular damage.

The density of gut ACE2 may affect the viral load of an individual exposed to SARS-CoV-2 and destruction of ACE2 in the gut by SARS-CoV-2 could cause diarrhea and other gastrointestinal symptoms found in COVID infected patients. 40 

Both the AT 1 R and AT 2 R are seven transmembrane proteins belonging to the G protein-coupled receptor (GPCR) super family. Ang II dependent activation of AT 1 R is transient and results in receptor internalization. Forrester et al. 41 state Ang II activation of AT 1 R promotes signaling that is diverse, convergent, and convoluted. As far as is currently known the AT 1 R is the only angiotensin receptor responsible for the pro-inflammatory actions of angiotensin peptides.

Activation of the AT 1 R by Ang II causes its interaction with the heterotrimeric G proteins, including Gq/11, G12/13, and Gi. Second NO production is also increased by the action of alamandine acting on MgrD (Figure 1 ). Therefore, Ang-(1-7) opposes the actions of Ang II-AT 1 R through its interactions with three different receptors.

The innate immune system is the first line of defense against trauma and infection. Inflammation damages tissues and organs, and repair is often associated with fibrosis. Three main pathways (NFκB, MAPK, and JAK-STAT) play major roles in inflammation, and dysregulation of one or more of these pathways can lead to inflammation-associated disease. 52 What is commonly missing from publications, is the role of Ang II-AT 1 R and aldosterone-MR in inflammation even though they complement the generation of ROS by cells involved in the immune response, stimulate key signaling pathways involved in the inflammatory response, for example, NF-κB and MAPK, and recruit immune cells to sites of injury/infection ( Figure 5 ). This section deals with tissue angiotensin producing systems and their response to injury or infection.

Tissue (renin) angiotensin producing systems are activated locally.

Signaling pathways are described above but Ang II-AT 1 R also increases vascular permeability by promoting the secretion of vascu- Ang II-AT 1 R production of ROS amplifies the inflammatory actions of the innate immune system ( Figure 5 ). Aldosterone acts in synergy with Ang II as many cells of the innate immune system also possess MRs (see above). Jurewicz et al. 60 showed that Ang II also stimulates T-cell pro-

F I G U R E 5 Summary of the positive interactions between the renin-angiotensin system (RAS) and the innate immune system. Angiotensin (Ang) II has the capacity to affect the activities and properties of these immune cells. They in turn have the capacity to generate Ang II thus reinforcing the pro-inflammatory actions of Ang II, particularly through the generation of reactive oxygen species (ROS) proliferate in response to Ang II. In contrast to the mutually antagonist actions of AT 1 R and AT 2 R in maturation of DCs (see above), the interaction of Ang II with both AT 1 R and AT 2 Rs are involved in this

So profound is the role of Ang II in the immune response to inflammation that it can induce autoimmune-induced inflammation.

Autoimmune-induced encephalomyelitis (EAE) was induced in mice with an encephalitogenic proteolipoprotein peptide (PLP). 62 Immunization with PLP stimulated Ang II formation in CD4 + cells and Interestingly, ACE contained within neutrophils increases their bactericidal activity independent of Ang II/AT 1 R pathway. 68 

Mast cells derive from CD34 + multi-potent bone marrow progenitor cells. They circulate in the blood as basophils and enter mucosal surfaces and connective tissue compartments of multiple organs. They are modulators and mediators of innate immunity, inflammation, and fibrosis. Mast cells contain renin and stimulation of mast cell degranulation results in Ang I formation. 69 Mast cells also contain chymase, the major Ang II forming enzyme in the human heart. 70

Because there are multiple pathways and cellular origins for the production of Ang II, any tissue subjected to inflammation is likely to be heavily infiltrated with Ang II, thus exacerbating Ang II-AT 1 R inflammatory pathways. Although this can be offset to some extent by the anti-inflammatory actions of Ang II mediated by its AT 2 R, this is limited. Thus ACE2 is the major regulator levels of tissues and cellular Ang II.

We postulate that inflammation, whether caused by infection, stretch or foreign antigens, releases Ang II, which recruits and interacts with pro-inflammatory cells (described above). These cells bring

Ang II forming pathways to the infected site. Since the severe host response to COVID-19 is an overexpression of the inflammatory response to infection, inhibitors of Ang II-AT 1 R interactions could be of therapeutic value (see below).

ACE2 produces Ang-(1-7) from Ang II (Figure 1 ). Ang II is its major substrate. Therefore ACE2, both by removal of Ang II and the anti-inflammatory action of its proteolytic activity, namely Ang-(1-7), which acts via AT 2 R, Mas, and MgrD (see above), is the most powerful regulatory mechansim for controlling Ang II and its AT 1 Rmediated effects.

ACE2 expression is increased in tissues like the heart when there is evidence of chronic disease. 71 It is possible that this represents feedback regulation of Ang II's local inflammatory actions. Therefore in tissues in which there is already chronic inflammation and increased local Ang II production, for example, in obesity, 10 in the bronchial epithelium of overweight patients with chronic obstructive pulmonary disease (COPD 72 ), and heart, 71 ACE2 levels are increased. Since ACE2 is the portal via which SARS-CoV-2 enters cells to replicate, the more ACE2, the greater the viral load. Furthermore, once the spike protein of SARS-CoV-2 binds to ACE2, ACE2 is removed from the cell surface. This results in a significant loss of protection for tissues against inflammation.

poses infected tissues and organs to unregulated severe inflammation and this is one reason why this virus has significant mortality and morbidity.

The significance of the role of ACE2 in protecting against the proinflammatory actions of Ang II has been clearly demonstrated (see below). These experiments show that ACE2 protects the organism from Ang II and highlights pathways and effects of Ang II, unmasked by loss of ACE2. As ACE2 is reduced with the entry of SARS-CoV-2 into cells, Ang II activity, including inflammation, is expected to be amplified in COVID-19.

In an outstanding experiment, Oudit et al. 73 showed that there were two critical aspects to Ang II-induced inflammation: (1) The ability of Ang II to induce ROS; and (2) limitation of this action by ACE2.

Briefly, in the ACE2 −/y mouse, a pathological cardiomyopathy developed due to increased ROS, causing a 4-fold increase in neutrophilic infiltration, increased infiltration of inflammatory cytokines, IL-1β, IL-6, and monocytic chemoattractant protein (MCP), activation of MAP kinase and increased collagenase activity. 73 All these features of ACE2 −/y cardiomyopathy were blocked by the angiotensin receptor blocker (ARB), irbesartan. Therefore, this chronic inflammation must have been due to Ang II (or an Ang peptide) interacting with the AT 1 R and triggering its downstream pathways. This effect was not seen in ACE2 −/y P110γ /−/− mice. The key activator of NOX that produces ROS is the catalytic subunit of PI2Kγ namely p110γ. Thus, ACE2 deficiency via increased Ang II leads to unchecked production of ROS.

The study carried out in ACE2 −/y mice 73 shows that even in noninflamed/non-infected tissues, endogenous tissue Ang II (or Ang peptides) cause inflammation and cardiac dysfunction when not inhibited by ACE2. Therefore, ACE2 is carrying out a physiological role in preventing overt inflammation and organ damage caused by excess Ang II and lack of Ang- (1-7) . These authors also showed that that variable expression of NADH affected the severity of inflammation induced in ACE2 −/y mice, that is, the genetic background of mice influenced the effects of ACE2 −/y genetic deletions. Extrapolating these findings to humans suggests that genetic as well as environmental factors such as obesity and other comorbidities affect the host response to the destruction of ACE2 by SARS-CoV-2. This is borne out by evidence of more severe morbidity and mortality in the obese, 10 even taking into account the difficulties in the care of ICU patients.

Rabelo et al. 74 also studied ACE2 −/y mice. These mice had higher mean arterial pressures, deficiencies in antioxidants such as superoxide dismutase (SOD) and catalase although SOD2 was not decreased, and glutathione peroxidase (GPx) was in fact increased. There was also evidence of increased oxidative damage, for example, thiobarbituric acid reactive substances (TBARS). MasR knockout mice have a similar phenotype, that is, hypertension, endothelial dysfunction and an imbalance between NO and reactive oxygen species. 75

The role of the RAS in pulmonary vascular endothelium is extremely significant because the entire capillary network of the lung contains ACE whereas only about 20% of the capillary network in other organs express ACE. 76 This explains the well-known fact that the lung is the major site for the conversion of Ang I to Ang II. Thus, the lung must be rigorously protected from the pro-inflammatory actions of Ang II (Figure 2 ). ACE2 is present in Clara cells and in alveolar type II cells and it is damage to these cells that is a feature of acute respiratory distress syndrome (ARDS), 77 which is seen in many severe COVID-19 cases.

LPS-induced ARDS in rats was associated with increased pulmonary renin expression and activity, increased Ang II levels, increased expression of ACE and reduced expression of ACE2. 78 These effects were reversed to some extent by treatment with Vitamin D prior to the LPS challenge. In mice, genetic knockouts of ACE2 caused much more severe ARDS (induced by aspiration, endotoxin, or peritoneal sepsis). These animals were rescued by administration of an AT 1 R antagonist. 79 In patients who developed ARDS compared with other patients in respiratory failure, 80 the D/D deletion of the ACE gene (which is associated with increased expression of ACE) was more prevalent.

This reflects the findings reported in mice 73 showing that the genetic background influenced the severity of inflammation induced by the ACE2 knockout. Thus, it is not surprising that the SARS-CoV spike protein, which also uses ACE2 as its receptor, exacerbated the effects of aspiration-induced lung damage and was prevented by AT 1 R blockade. 9 Thus, the role of Ang II in acute lung injury (ALI) is well documented as is the beneficial effect of ACE2. This has led to the suggestion that recombinant human (rh)ACE2 could be a useful therapy for ALI 81 and potentially for SARS-CoV-2.

Zoufaly et al. 82 

This article has shown that the basis of the inflammatory response to infection with SARS-CoV-2 is an excess of Ang II produced both by local production in infected cells and by the destruction of ACE2, the enzyme controlling tissue concentrations of Ang II. It should be noted that there are other peptides and proteins that can interact with the AT 1 R (Figure 1) , there are several proteases that generate Ang II ( Figure 2 ) and a strong contingent of inflammatory cells recruited to sites of infection that contain Ang II producing systems. Therefore, the major therapeutic targets for treating COVID-19 should target this imbalance between pro-and anti-inflammatory RAS pathways.

There are several drugs that do restore this balance, most of which are used in the treatment of cardiovascular disease, chronic renal disease and diabetes mellitus. These can be repurposed for use in treating COVID-19 as described below (Figure 6 ).

The renin inhibitor, aliskiren, inhibits the ability of renin to form Ang I from AGT. Guo et al. found that aliskiren was safe for treating hypertension in COVID affected patients and recommend further clinical evaluation. 84 Aliskiren is among a number of protease inhibitors 85 that biologically ought to be able to inhibit SARS-CoV-2 viral entry by blocking its major protease (M Pro ). 86 

ACE inhibitors such as lisinopril and captopril block the formation of Ang II from Ang I. They are widely used and have been shown to reduce mortality and morbidity in COVID-19 patients. It could be argued that ACEIs would be less effective than ARBs because although they prevent the formation of Ang II, they would also reduce Ang-(1-7) synthesis (see Figure 1 ). 

ARBs block the AT 1 R; therefore, they block the actions of Ang II produced by any pathway as well as other Ang peptides that interact with this receptor (Figure 1 ). Experimental use of ARBs has provided much of the information concerning the pro-inflammatory actions of Ang II described in this article.

Duarte et al. 92 It is also feasible that blockade of the RAS by an ARB may have greater efficacy in the treatment of COVID-19 because only the AT 1 R is blocked, therefore any Ang II formed could have anti-inflammatory effects via its interaction with AT 2 R or via conversion by residual ACE2 to Ang-(1-7) which acts via AT 2 R, MasR, and MgrD ( Figure 1 ).

Since Ang II stimulates aldosterone secretion and there is a synergy in their pro-inflammatory actions there could be a case for using drugs like spironolactone and epleronone that block the MR in treatment of COVID-19. Abolishing the unique effects of MR generated by formation ATP on purinergic nerves with consequent activation of clotting and increased capillary permeability 19 could provide additional therapeutic benefits.

Recombinant human sACE2 can "mop up" the virus in the cardiovascular system and is enzymatically active so it can increase the formation of Ang-(1-7) from excess Ang II. In 2020, Monteil et al. 93 showed that (rh)sACE2 reduced SARS-CoV-2 infection in human organoids and later showed in vitro, that the combination of ACE2 with the anti-viral medication, remedesvir, improved the anti-viral activity and reduced toxicity. 94 ACE2 has also been used to treat COVID-19; its effects are described above. 82 This appears to be the only cited report of clinical use of sACE2 in human COVID-19. The anti-inflammatory effects of ACE2 have been described (see above). (rh)sACE2 has also passed through phase I and II clinical trials (NCT00886353, NCT01597635) 95,96 for ARDS and it has now received regulatory F I G U R E 6 Drugs to treat COVID-19. Repurposing existing drugs that target the RAS and would reduce the levels of Ang II or its actions on AT 1 R may be of benefit for patients with COVID-19. These include renin inhibitors, ACE inhibitors and angiotensin receptor blockers. Drugs that block the secretion of aldosterone may also be of use. Alternatively, stimulation of the opposing RAS pathway, for example using (rh)ACE2, ACE2 agonists, or Ang-(1-7) may also be beneficial approval in the USA for continued study. Several studies are now trialing its use for COVID-19 (NCT04335136, NCT05065645, and NCT04924660). One of these studies is now complete (NCT04335136), however, data were inconclusive.

Alternatively, Ang (1-7) could be produced from Angiotensin I (see Figure 1 ) when ACE2 has been destroyed by This is the mechanism of action of the metalloprotease neprilysin which, when combined with an ACE inhibitor, is used clinically in the treatment of cardiovascular disease.

6 | AC TIVATOR S OF ACE2

The ACE2 agonist, DIZE, has been shown to reverse ALI, by preventing inflammation, ROS generation, NFκ-B activation, and Nrf2 inhibition (see above 46 ). Qaradakhi et al. 98 have suggested that DIZE, through ACE2 activation, could be used to treat a wide range of disease including myocardial infarction, hypertension, and arteriosclerosis.

However, Haber et al. 99 showed that DIZE and another activator, XNT, had effects on blood pressure that must have been independent of ACE2 activation as they occurred in ACE2 knockout mice. These did not have any effects on Ang II levels and renal ACE2 activity.

There is a clinical trial (NCT04633772) studying the efficacy of intravenous Ang-1-7 for the treatment of COVID-19. The primary endpoint is the number of supplemental oxygen-free days by day 28.

The trial will be completed in late 2021. However, it may not be as efficacious as rhsACE2 (see above) which prevents inflammation via two pathways.

Ang II plays a major role in inflammation. The receptor for SARS-COV-2, ACE2, is intimately involved in regulating Ang II -AT 1 R interactions and inhibits the pro-inflammatory actions of Ang II.

Therefore, the destruction of ACE2 by SARS-CoV-2 causes dysregulation of the host response to the virus. Drugs that block the formation of Ang II or prevent its interactions with the AT 1 R are therefore useful adjuncts in the management of patients with COVID-19. There are several trials suggesting that ACEIs and ARBs decrease mortality and morbidity from COVID-19. Renin inhibitors, which have the same effect as ACEIs and ARBs, are also safe for use in COVID-19 and may provide an additional therapeutic benefit by blocking viral entry into cells. It would seem however that the most efficacious treatment of patients with COVID-19 is likely to be rhsACE2.

Association between reninangiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis

NL63: a better surrogate virus for studying SARS-CoV-2

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

Emergence and evolution of the renin-angiotensin-aldosterone system

Human viruses: discovery and emergence

Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?

Angiotensin A/Alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology

Angiotensin II-generating enzymes

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Obesity and COVID-19: Renin-Angiotensin as a mediator of morbidity and mortality

Into the eye of the cytokine storm

COVID-19 cytokine storm: the anger of inflammation

The role of agonistic autoantibodies to the angiotensin II type 1 receptor (AT1-AA) in pathophysiology of preeclampsia

Soluble (pro)renin receptor: a novel ligand for angiotensin II type 1 receptor?

Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans

Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?

Angiotensin II stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA

The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature

New horizons: does mineralocorticoid receptor activation by cortisol cause ATP release and COVID-19 complications?

Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease

An update on the tissue renin angiotensin system and its role in physiology and pathology

The activation of renin in human amniotic fluid by proteolytic enzymes

Activation of human inactive ("pro-") renin by cathepsin D and pepsin

Plasma kallikrein and plasmin as activators of prorenin: links between the renin-angiotensin system and other proteolytic systems in plasma

Renin, (pro)renin and receptor: an update

Expression of cathepsins B, D, and G in WHO grade I meningioma

Plasma cathepsin D isoforms and their active metabolites increase after myocardial infarction and contribute to plasma renin activity

A redox switch in angiotensinogen modulates angiotensin release

Call for papers: the pathophysiology of COVID-19 and SARS-CoV-2 infection

Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?

Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart

Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue

Angiotensin-(1-12): a chymasemediated cellular angiotensin II substrate

Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease

Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure

AT(2) receptor and tissue injury: therapeutic implications

Cell entry mechanisms of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

ACE2 and gut amino acid transport

Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome

Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology

Angiotensin II, NADPH oxidase, and redox signaling in the vasculature

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin IIinduced hypertrophy in vascular smooth muscle cells

Angiotensin II-induced genomic damage in renal cells can be prevented by angiotensin II type 1 receptor blockage or radical scavenging

Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kappaB and Nrf2 pathways

Mitochondrial angiotensin receptors and cardioprotective pathways

Intratubular, intracellular, and mitochondrial angiotensin II/AT1 (AT1a) receptor/NHE3 signaling plays a critical role in angiotensin ii-induced hypertension and kidney injury

AT2 receptors: beneficial counterregulatory role in cardiovascular and renal function

Identification of the Mtus1 splice variant as a novel inhibitory factor against cardiac hypertrophy

Emerging evidence for a functional angiotensinconverting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure?

Inflammatory responses and inflammation-associated diseases in organs

Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells

Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries

Direct evidence of leukocyte adhesion in arterioles by angiotensin II

Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction

Angiotensin II revisited: new roles in inflammation, immunology and aging

Control of dendritic cell differentiation by angiotensin II

Regulation of T-cell function by endogenously produced angiotensin II

Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation

Rapid production of TNFalpha following TCR engagement of naive CD8 T cells

Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates TH1-and TH17-mediated autoimmunity

Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system

Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines

The inflammatory response in myocardial infarction

Cell surface-bound elastase and cathepsin G on human neutrophils: a novel, non-oxidative mechanism by which neutrophils focus and preserve catalytic activity of serine proteinases

Angiotensin II generation at the cell surface of activated neutrophils: novel cathepsin G-mediated catalytic activity that is resistant to inhibition

Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils

Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction

Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart

ACE2 gene expression is up-regulated in the human failing heart

Increased ACE2 expression in bronchial epithelium of COPD patients who are overweight

Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice

Genetic deletion of ACE2 induces vascular dysfunction in C57BL/6 mice: role of nitric oxide imbalance and oxidative stress

Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice

Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity

Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung

Vitamin D alleviates lipopolysaccharideinduced acute lung injury via regulation of the reninangiotensin system

Angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome

Recombinant human ACE2: acing out angiotensin II in ARDS therapy

Human recombinant soluble ACE2 in severe COVID-19

The Nrf2 activator (DMF) and Covid-19: is there a possible role? Med Arch

Preliminary clinical study of direct renin inhibitor aliskiren in the treatment of severe COVID-19 patients with hypertension

Ebselen, a new candidate therapeutic against SARS-CoV-2

Potential SARS-CoV-2 main protease inhibitors

Molecular docking reveals the potential of aliskiren, dipyridamole, mopidamol, rosuvastatin, rolitetracycline and metamizole to inhibit COVID-19 virus main protease

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system

Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people

Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients

Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection

Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Targeting Neprilysin (NEP) pathways: a potential new hope to defeat COVID-19 ghost

The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases

Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guide topha rmaco logy. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY, 100 

The authors have no conflicts of interest to declare.

Eugenie R. Lumbers drafted the manuscript. All authors made substantial contributions to the conception and design of the manuscript, revised it critically for intellectual context and gave final approval of the final version.